In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.
|Articles|September 18, 2013
- Fall 2013
- Volume 12
- Issue 3
HPV Infections Plummet with Vaccine
Author(s)Elizabeth Whittington
Human papillomavirus infections in female teenagers have decreased by more than half since the introduction of HPV vaccines.
Advertisement
Human papillomavirus (HPV) infections have skyrocketed during the past 20 years, yet among female teenagers, the number of HPV infections has decreased by 56 percent since the introduction of an HPV vaccine in 2006. Experts hope the decrease in infections will ultimately result in a decrease of HPV-related cancers, including anal, cervical, certain head and neck, penile and vulvar cancers.
Articles in this issue
about 13 years ago
Lung Cancer Video Touches on Emotions and Supportabout 13 years ago
Triple-Negative Breast Cancer: Divide and Conquerabout 13 years ago
Future Frontier: Fighting Cancer at the Genetic Levelabout 13 years ago
Second Chance: When Grandparents Become the Caregiversabout 13 years ago
Supreme Court Votes Against Human Gene Patentsabout 13 years ago
Documentary About Cancer Plannedabout 13 years ago
Critical Mass Annual Conferenceabout 13 years ago
Superfoods Study Keeps More Men on Active Surveillanceabout 13 years ago
DCA Claims Don’t Tell Whole StoryAdvertisement
Related to this article
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Advertisement
Advertisement
Trending on CURE
1
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
4
CAR T-Cell Therapy Offers Hope for Lasting Remission in Hairy Cell Leukemia
5